The American journal of gastroenterology
-
Am. J. Gastroenterol. · Nov 2020
Randomized Controlled Trial Comparative StudyFendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial.
To compare Engerix-B and Fendrix hepatitis B virus for primo vaccination in inflammatory bowel disease (IBD). ⋯ We could not demonstrate a higher response rate of Fendrix (single dose) over Engerix-B (double dose). A 4-dose schedule is more effective than a 3-dose regimen. Older age and treatment with immunomodulators or anti-tumor necrosis factors impaired the success. A high proportion of IBD patients with protective anti-HBs titers after vaccination loose them over time. The risk of losing protective anti-HBs titers is increased in patients achieving anti-HBs <100 IU/L after the vaccination.
-
Am. J. Gastroenterol. · Nov 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
New therapeutic options for patients with Crohn's disease (CD) with perianal lesions failing anti-tumor necrosis factor (TNF) agents are needed. We aimed to assess the effectiveness of ustekinumab in perianal CD (pCD) and predictors of clinical success in a real-life multicenter cohort. ⋯ Ustekinumab appears as a potential effective therapeutic option in perianal refractory CD. Further prospective studies are warranted.